Stock SNTI SENTI BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

End-of-day quote Nasdaq
Other stock markets
 18:00:00 2024-04-24 EDT 		5-day change 1st Jan Change
0.2787 USD -0.78% Intraday chart for Senti Biosciences, Inc. -9.37% -57.77%
04-26 Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024 CI
04-26 Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024
CI
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024
CI
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M
MT
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
GL
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
GL
Spark Therapeutics, Inc. Announces Workforce Reduction
CI
Top Premarket Gainers
MT
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
GL
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
AQ
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
CI
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000
MT
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
GL
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
GL
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
AQ
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd
CI
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
GL
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNTI Stock
  4. News Senti Biosciences, Inc.